Market capitalization | $3.48m |
Enterprise Value | $5.90m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.36m |
Free Cash Flow (TTM) Free Cash Flow | $-26.07m |
Cash position | $1.50m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:
1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.04 -0.04 |
43%
43%
|
|
EBITDA | -25 -25 |
45%
45%
|
EBIT (Operating Income) EBIT | -25 -25 |
45%
45%
|
Net Profit | -23 -23 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Head office | United States |
CEO | John Brancaccio |
Employees | 22 |
Founded | 2013 |
Website | www.hepionpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.